1. Home
  2. FSEA vs IMMP Comparison

FSEA vs IMMP Comparison

Compare FSEA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Seacoast Bancorp Inc.

FSEA

First Seacoast Bancorp Inc.

HOLD

Current Price

$16.83

Market Cap

52.7M

Sector

Finance

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.37

Market Cap

54.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSEA
IMMP
Founded
1890
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
54.4M
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
FSEA
IMMP
Price
$16.83
$0.37
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
23.9K
805.7K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.13
$0.29
52 Week High
$16.90
$3.53

Technical Indicators

Market Signals
Indicator
FSEA
IMMP
Relative Strength Index (RSI) 77.51 35.52
Support Level $16.60 $0.29
Resistance Level N/A $0.39
Average True Range (ATR) 0.05 0.03
MACD -0.15 0.00
Stochastic Oscillator 44.83 18.13

Price Performance

Historical Comparison
FSEA
IMMP

About FSEA First Seacoast Bancorp Inc.

First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: